Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio
Neurocrine Bioscienc (NQ: NBIX)
104.67 USD  -1.66 (-1.56%)
Official Closing Price  /  Updated: 5:49 PM EST, Jan 17, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 757,600
Open 106.08
Bid (Size) 103.01 (1)
Ask (Size) 110.06 (1)
Prev. Close 106.33
Today's Range 104.19 - 107.30
52wk Range 71.85 - 119.65
Shares Outstanding 89,897,863
Dividend Yield N/A
Performance
YTD
-3.35%
-3.35%
1 Month
-0.88%
-0.88%
3 Month
+9.28%
+9.28%
6 Month
+22.12%
+22.12%
1 Year
+18.14%
+18.14%
Top News
More News
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update
from GlobeNewswire News Releases
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones
- INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $238 Million with Approximately 42,100 TRx Read More
from PR Newswire
More News
Read More
Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy
from PR Newswire
Neurocrine Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference Live Audio Webcast will be on January 13, 2020
from PR Newswire
Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting
from GlobeNewswire News Releases
Notable Monday Option Activity: NBIX, TCX, ADVM
category Stocks
from Market News Video
Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy
from GlobeNewswire News Releases
Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy
from PR Newswire
Idorsia pairs with Neurocrine in potential $400 mln epilepsy drug deal
category companyNews
from Reuters: Company News
Why Neurocrine Biosciences Soared 50.5% in 2019
category NBIX , Market News , ABBV
from Motley Fool
The 10 Best Healthcare Stocks of the Decade
category RGEN , JAZZ , Market News , and 10 more.
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.